ArticleMolecular pharmacology2016

Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.

Rayna Rosati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.